News | Contrast Media Injectors | May 03, 2016

GlobalData says near doubling will be driven by increases in CT/MR/angiography procedures

GlobalData, contrast media injectors market,

May 3, 2016 — The global market for contrast media injectors is set to increase from $830 million in 2015 to almost $1.8 billion by 2022, according to research and consulting firm GlobalData. This represents a compound annual growth rate (CAGR) of 11 percent.

The company’s latest report states that this rise, which will occur across 15 major markets, will mainly be driven by increases in the number of annual computed tomography (CT), magnetic resonance imaging (MRI) and angiography procedures, as well as growth in the utilization of contrast media injectors and increasing disease burdens.

Sarah Janer, GlobalData’s analyst covering medical devices, explained, “Contrast injectors can only be used alongside imaging devices, so the contrast media injector market relies on the growing demand for MRI and CT scanners. Indeed, as MRI machines are not normally packaged with an injector, hospitals must purchase MRI injectors separately from the suppliers.

“CT contrast injectors, on the other hand, are usually packaged with CT scanner sales, so although the market for both types of injectors is growing, CT contrast media injectors experience higher replacement rates than new sales.”

The CT segment is the largest and fastest growing in the market and will rise at a CAGR of 12.3 percent during the forecast period, thanks to the rising popularity of CT imaging systems, which have become a standard for diagnostic imaging around the world. Single-head injectors make up the majority of the market’s volume due to their low average selling price, which makes them especially attractive in emerging economies and hospitals that are pressed for funding.

However, Janer noted, “With the decline of CT injector prices in all sub-sections and geographies, GlobalData expects that dual-head injectors will experience high growth as hospitals seek to upgrade their injectors with more efficient models for lower costs.”

For more information: www.globaldata.com


Additional Content

News | Contrast Media

Oct. 27, 2026 – Bracco has announced plans to invest $230 million to establish its first U.S. manufacturing facility for ...

Time October 28, 2026
arrow
News | Cardiac Imaging

Aug. 11, 2026 — Bracco Imaging recently announced that VueJect, its dedicated ultrasound contrast delivery system ...

Time August 12, 2026
arrow
News | Contrast Agents

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
News | FDA

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
Subscribe Now